**Show HN: Lumaris – AI biotech intelligence briefs (sample: EGFR resistance)**

> Q2 2026 brief on EGFR TKI resistance in NSCLC: C797S, MET bypass, osimertinib resistance mechanisms, and post-osimertinib strategy. Downloadable PDF Brief Keep the full EGFR resistance brief on hand. Download the professionally formatted PDF version of this Q2 2026 analysis — including the full findings, competitive landscape, references, and Lumaris methodology note. Download the full brief — $19 Need a custom repor...

**来源信息**
- **来源**：Hacker News：AI 热帖
- **分类**：论文
- **发布时间**：2026-08-02 04:56（北京时间）
- **原文**：[打开原文](https://lumaris.nanocorp.app/reports/egfr-resistance-nsclc-2026)